Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Campus-Vienna-Biocenter 1, Vienna, Austria.
Medical University of Vienna, Vienna Biocenter (VBC), Vienna, Austria.
Nat Methods. 2018 Feb;15(2):141-149. doi: 10.1038/nmeth.4534. Epub 2017 Dec 11.
The identification of transcriptional enhancers in the human genome is a prime goal in biology. Enhancers are typically predicted via chromatin marks, yet their function is primarily assessed with plasmid-based reporter assays. Here, we show that such assays are rendered unreliable by two previously reported phenomena relating to plasmid transfection into human cells: (i) the bacterial plasmid origin of replication (ORI) functions as a conflicting core promoter and (ii) a type I interferon (IFN-I) response is activated. These cause confounding false positives and negatives in luciferase assays and STARR-seq screens. We overcome both problems by employing the ORI as core promoter and by inhibiting two IFN-I-inducing kinases, enabling genome-wide STARR-seq screens in human cells. In HeLa-S3 cells, we uncover strong enhancers, IFN-I-induced enhancers, and enhancers endogenously silenced at the chromatin level. Our findings apply to all episomal enhancer activity assays in mammalian cells and are key to the characterization of human enhancers.
在人类基因组中识别转录增强子是生物学的主要目标。增强子通常通过染色质标记来预测,但它们的功能主要通过基于质粒的报告基因检测来评估。在这里,我们表明,与质粒转染入人类细胞有关的两个先前报道的现象使这些检测变得不可靠:(i)细菌质粒复制起点(ORI)作为竞争性核心启动子发挥作用;(ii)I 型干扰素(IFN-I)反应被激活。这些现象导致荧光素酶检测和 STARR-seq 筛选中的混淆假阳性和假阴性。我们通过将 ORI 作为核心启动子,并抑制两种诱导 IFN-I 的激酶来克服这两个问题,从而在人类细胞中进行全基因组 STARR-seq 筛选。在 HeLa-S3 细胞中,我们发现了强增强子、IFN-I 诱导的增强子以及在染色质水平上内源性沉默的增强子。我们的发现适用于哺乳动物细胞中所有的附加体增强子活性检测,并且是人类增强子特征描述的关键。